Oramed Pharmaceuticals (ORMP) Stock
Biotech company focused on oral insulin delivery. Here's the price, business snapshot, and what's worth knowing about Oramed Pharmaceuticals in August 2026.
Oramed Pharmaceuticals Inc (ORMP) is a clinical-stage biotechnology company focused on oral delivery solutions for peptide drugs. Its lead programme centres on an oral insulin capsule intended for people with type 2 diabetes; the company also explores other peptide-based candidates using its proprietary delivery platform. As a small-cap firm (market capitalisation around $95.95m), Oramed’s value is highly sensitive to clinical-trial results, regulatory milestones and partnership news. Investors should expect elevated volatility, possible dilution from future funding rounds, and a long development timeline typical of drug developers. While the oral delivery approach could broaden patient access and reshape administration of some medicines if proven, outcomes are uncertain and depend on trial efficacy, safety and regulatory approval. This summary is general information only and not personalised investment advice; consider your risk tolerance and seek professional guidance before making decisions.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Oramed Pharmaceuticals' stock, with a target price of $3.25 indicating potential growth.
Financial Health
Oramed Pharmaceuticals is showing steady cash flow and book value, but growth may be slow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage catalyst
Clinical trial updates can meaningfully affect the share price, though results and timelines are uncertain and may cause volatility.
Oral delivery innovation
The company’s technology aims to enable oral administration of peptides — a notable scientific challenge with potential upside if validated, but regulatory proof is required.
Partnership and scale
Partnerships or licensing could accelerate market access and scale, yet small-cap status and competition mean outcomes are far from guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
